Boston Sci Says It Will Be Careful About Resorbable Scaffold Investment
This article was originally published in The Gray Sheet
Executive Summary
The company announced July 20 the start of its 30-patient, single-arm FAST study assessing its everolimus-eluting scaffold system, but executives says Boston Scientific will be closely considering whether the system warrants long-term investment, considering the promise of its Synergy stent.